Well this is a good announcement for Invion 103. So to date, Invion will now have recieved/reviewed data from 32 patients. The fact that they are awaiting on final data from the last cohort is very encouraging. If they hadn't seen any biological effect from patients dosed with CPN10 in the last 2 cohorts, or if there were any adverse effects from the drug, they wouldn't be keeping enrolement open for the final cohort. Exciting few weeks ahead.
Add to My Watchlist
What is My Watchlist?
